These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31805108)

  • 1. Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations.
    Guarnieri F; Kulp JL; Kulp JL; Cloudsdale IS
    PLoS One; 2019; 14(12):e0225780. PubMed ID: 31805108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.
    Li L; Shen C; Huang YX; Li YN; Liu XF; Liu XM; Liu JH
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30235833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
    Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
    J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.
    Wang WZ; Liu C; Luo JQ; Lei LJ; Chen MH; Zhang YY; Sheng R; Li YN; Wang L; Jiang XH; Xiao TM; Zhang YH; Li SW; Wu YX; Xu Y; Xu YN; Si SY
    Acta Pharmacol Sin; 2024 Oct; 45(10):2119-2133. PubMed ID: 38811775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction.
    Sun H; Wang J; Liu S; Zhou X; Dai L; Chen C; Xu Q; Wen X; Cheng K; Sun H; Yuan H
    J Chem Inf Model; 2021 Oct; 61(10):5269-5279. PubMed ID: 34553597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.
    Lammi C; Sgrignani J; Arnoldi A; Lesma G; Spatti C; Silvani A; Grazioso G
    J Med Chem; 2019 Jul; 62(13):6163-6174. PubMed ID: 31260298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
    Poirier S; Hamouda HA; Villeneuve L; Demers A; Mayer G
    PLoS One; 2016; 11(6):e0157230. PubMed ID: 27280970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
    Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
    J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
    Kirchhofer D; Burdick DJ; Skelton NJ; Zhang Y; Ultsch M
    Biochem Soc Trans; 2020 Aug; 48(4):1323-1336. PubMed ID: 32794575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
    Valenti V; Noto D; Giammanco A; Fayer F; Spina R; Altieri GI; Ingrassia V; Scrimali C; Barbagallo CM; Brucato F; Misiano G; Cefalù AB; Averna MR
    Atherosclerosis; 2020 Jan; 292():209-214. PubMed ID: 31564372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of [5,5'-bibenzo[d][1,3]dioxol]-6-substituted amine derivatives as potent proprotein convertase subtilisin/kexin type 9 inhibitors.
    Zhu D; Qin H; Wang X; Jia Y; Wang X; Zhang L
    Chem Biol Drug Des; 2023 Jul; 102(1):153-167. PubMed ID: 37170061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
    Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
    Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
    Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
    Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
    Brousseau ME; Clairmont KB; Spraggon G; Flyer AN; Golosov AA; Grosche P; Amin J; Andre J; Burdick D; Caplan S; Chen G; Chopra R; Ames L; Dubiel D; Fan L; Gattlen R; Kelly-Sullivan D; Koch AW; Lewis I; Li J; Liu E; Lubicka D; Marzinzik A; Nakajima K; Nettleton D; Ottl J; Pan M; Patel T; Perry L; Pickett S; Poirier J; Reid PC; Pelle X; Seepersaud M; Subramanian V; Vera V; Xu M; Yang L; Yang Q; Yu J; Zhu G; Monovich LG
    Cell Chem Biol; 2022 Feb; 29(2):249-258.e5. PubMed ID: 34547225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging Bidirectional Nature of Allostery To Inhibit Protein-Protein Interactions (PPIs): A Case Study of PCSK9-LDLR Interaction.
    Sinha K; Basu I; Shah Z; Shah S; Chakrabarty S
    J Chem Inf Model; 2024 May; 64(9):3923-3932. PubMed ID: 38615325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.